Management Madhumeha (Diabetes mellitus type 2)

An open label clinical trial to evaluate the efficacy of Sugralo capsule in Madhumeha (Diabetes mellitus type 2) - SDM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/022662

Enrollment

Registered

2020-01-08

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Sugralo Capsule: Ingredients: Sugralo capsule (500 mg each) contains Jamuna (Syzygium cumini) (Seed), Gurmara (Gymnema sylvestre) (Leaves), Methi dana (Trigonella foenum graecum) (Seed)

which are triturated with juice of Guduchi (Tinospora cordifolia) (Stem), Karela (Momordica charantia) (Fruit extract). Dose: 2 capsules (500 mg each) orally twice daily 30 minutes before meal with lu

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed for the first time or Diagnosed cases not taking any medicine for 3 last months. 2. Patients with cardinal symptoms of Madhumeha described in Ayurveda classics. 3. Patients having F.B.S. in the range of 126 â?? 200 mg/dl and/or P.P.B.S. between 180-300 mg/dl will be selected for the study. 4. Patients willing and able to provide signed ICF prior to study will be included in the study.

Exclusion criteria

Exclusion criteria: 1. Patient with type 1 Diabetes mellitus. 2. Patients with type 2 Diabetes mellitus who are on insulin or oral hypoglycemic drugs. 3. Patients with FBS >= 200 mg/dl and/or PPBS >= 300 mg/dl. 4. Patients of Gestational Diabetes and Juvenile Diabetes. 5. Patient having Type-II DM with any other serious systemic disease. 6. Patients with complications like cardiac disorder, diabetic foot, Nephropathy and other secondary complications. 7. Diabetes Mellitus produced due to other illnesses like Acromegaly, Cushingâ??s syndrome, pancreatic disorders etc. 8. Individuals not willing to provide written Informed Consent Form. 9. Individuals participating in any other clinical trial. 10. Pregnant or lactating females.

Design outcomes

Primary

Measure	Time frame
Changes in FBSTimepoint: 90 Days	—

Secondary

Measure	Time frame
Changes in Subjective parameters, PPBS, HbA1c and Urine SugarTimepoint: 90 Days	—

Countries

India

Contacts

Public ContactDr Abhishek Upadhyay

Multani Pharmaceuticals Ltd. New Delhi

dr.hstiwari@multani.org9654350714

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026